Invasive Aspergillosis Drug Pipeline Report 2022: Comprehensive Insights on Active Companies and Pipeline Drugs Featuring F2G, SCYNEXIS, Pulmocide, & TFF Pharmaceuticals - ResearchAndMarkets.com
20 Dec 2022
Phase 3Orphan DrugPhase 2ImmunotherapyVaccine
DUBLIN--(BUSINESS WIRE)--The "Invasive Aspergillosis - Pipeline Insight, 2022" drug pipelines has been added to ResearchAndMarkets.com's offering.
This report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Invasive Aspergillosis pipeline landscape.
It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
The assessment part of the report embraces, in depth Invasive Aspergillosis commercial assessment and clinical assessment of the pipeline products under development.
In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Invasive Aspergillosis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Invasive Aspergillosis Emerging Drugs Chapters
This segment of the Invasive Aspergillosis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Invasive Aspergillosis Emerging Drugs
Olorofim: F2G
Olorofim (formerly F901318) is F2G's leading candidate from this class and has fungicidal activity against a broad range of mould infections including a variety of rare and resistant moulds that cause life-threatening infections for which current therapies have limitations or are ineffective.
Olorofim has received orphan drug status from the European Medicines Agency and orphan drug status, Qualified Infectious Disease Product (QIDP) designation and Breakthrough Therapy designation from FDA.
Ibrexafungerp: SCYNEXIS
Ibrexafungerp (formerly SCY-078) is the first representative of a novel class of structurally-distinct glucan synthase inhibitors, triterpenoids. It has shown activity against Aspergillus and Candida, including against multidrug-resistant (MDR) species Candida auris as well as Pneumocystis. Ibrexafungerp combines the well-established activity of glucan synthase inhibitors with the flexibility of oral and IV formulations, offering a broad use across different settings (in-patient and out-patient).
Invasive Aspergillosis: Therapeutic Assessment
This segment of the report provides insights about the different Invasive Aspergillosis drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Invasive Aspergillosis
There are approx. 3+ key companies which are developing the therapies for Invasive Aspergillosis. The companies which have their Invasive Aspergillosis drug candidates in the most advanced stage, i.e. phase III include, F2G.
Report Highlights
A better understanding of disease pathogenesis contributing to the development of novel therapeutics for Invasive Aspergillosis.
In the coming years, the Invasive Aspergillosis market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
The companies and academics that are working to assess challenges and seek opportunities that could influence Invasive Aspergillosis R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
A detailed portfolio of major pharma players who are involved in fueling the Invasive Aspergillosis treatment market. Several potential therapies for Invasive Aspergillosis are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the Invasive Aspergillosis market size in the coming years.
The in-depth analysis of the pipeline assets (in early-stage, mid-stage and late stage of development for the treatment of Invasive Aspergillosis) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.
Phases
The report covers around 3+ products under different phases of clinical development like
Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration
Products have been categorized under various ROAs such as
Inhalation
Inhalation/Intravenous/Oral
Intranasal
Intravenous
Intravenous/ Subcutaneous
NA
Oral
Oral/intranasal/subcutaneous
Parenteral
Subcutaneous
Molecule Type
Products have been categorized under various Molecule types such as
Antibody
Antisense oligonucleotides
Immunotherapy
Monoclonal antibody
Peptides
Protein
Recombinant protein
Small molecule
Stem Cell
Vaccine
Product Type
Invasive Aspergillosis Report Insights
Invasive Aspergillosis Pipeline Analysis
Therapeutic Assessment
Unmet Needs
Impact of Drugs
Invasive Aspergillosis Report Assessment
Pipeline Product Profiles
Therapeutic Assessment
Pipeline Assessment
Inactive drugs assessment
Unmet Needs
Key Players
F2G
SCYNEXIS
Key Products
Voriconazole dry powder inhalation
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/7wjzpt
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Indications
Targets
-Drugs
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.